Professor David Marks has been appointed Medical Director for the IMPACT clinical trials platform, a partnership between Anthony Nolan, Leuka, NHS Blood and Transplant, and the University of Birmingham.

Prof Marks has an extensive history in clinical trial delivery; he is director and consultant at Bristol transplant centre and holds an Honorary Professorship at the University of Bristol. He was President of the British Society of Blood and Marrow Transplantation between 2002 and 2009 and established the Society’s Clinical Trials Committee in 1999.

As Medical Director for the IMPACT partnership, Prof Marks will provide clinical leadership to ensure IMPACT achieves its strategic aims, namely the delivery of a portfolio of clinical trials designed to increase patient survival rates.

Prof Marks said, “I am delighted to be appointed as Medical Director of the IMPACT Partnership, the only dedicated resource for stem cell transplant clinical trials in the UK.

“There is an urgent need to improve outcomes to ensure more patients reach the milestone of five-year survival post-transplant. By collaborating with transplant centres, IMPACT will provide a platform for setting up trials and sharing knowledge, ultimately helping patients benefit from innovative treatments more quickly.”